Heron Therapeutics, Inc. (HRTX) Earnings Call Transcript & Summary

February 27, 2025

NASDAQ US Health Care Biotechnology earnings 27 min

Earnings Call Speaker Segments

Melissa Jarel

executive
#1

Thanks, operator, and good morning to all of you. We appreciate your participation on this Heron Therapeutics conference call today, where we'll be reviewing the company's financial results for the fourth quarter, which came to a close on December 31, 2024. Joining me from Heron are Craig Collard, our Chief Executive Officer; Ira Duarte, Executive Vice President, Chief Financial Officer; Bill Forbes, Executive Vice President, Chief Development Officer; and Kevin Werner, Senior Vice President, Medical Affairs, Strategy and Engagement. If you're on the conference call, slides are available through the webcast, and you can also find them on the Investor Relations page of our website once today's call wraps up. Before we dive in, I want to take a moment to remind everyone listening that during this call, the company will be sharing forward-looking statements. Just so we're clear: anything we say that isn't a statement of historical fact qualifies as forward-looking. That includes anything about the company's projections, expectations, plans, beliefs, and future performance — all of which fall under the forward-looking umbrella for purposes of the safe harbor provision in the Private Securities Litigation Reform Act of 1995. Statements like these are based on judgment and analysis as of today's call, and they come with a number of significant risks and uncertainties that could cause actual results to differ materially from what those forward-looking statements describe. Details about the dangers and unknowns connected to the predictive remarks given during this call and webcast can be found within the safe harbor language included in today's press release, as well as in Heron's periodic public submissions to the SEC. Unless the law demands otherwise, Heron takes on no responsibility for revising these predictive remarks to account for later occurrences or real results, and has no plan to do so. Having said that, I'd like to hand things over now to Craig Collard, Heron's Chief Executive Officer.

Craig Collard

executive
#2

Thank you, Melissa. Hello, everybody, and welcome to the Heron Therapeutics Fourth Quarter 2024 Earnings Call. We're very thrilled today to discuss our quarterly results along with how we performed across the entirety of 2024. From the time I came aboard in April 2023, our objective as a management team has been to set the business up for future growth and reach profitability by Q4 of 2024. While concentrating on getting the company ready for growth, we managed to broaden the label for ZYNRELEF, which doubled the count of approved indicated procedures. We likewise signed, trained and brought on board our CrossLink partnership, comprising more than 800 distributor representatives who concentrate on the orthopedic field. In addition, we obtained inclusion in the NOPAIN Act, which widens reimbursement for ZYNRELEF beyond the surgical bundle, giving more patients access to a non-opioid alternative for postoperative pain. In late September, we got approval for the Vial Access Needle, or VAN, and brought the new device to market in mid-December. The VAN greatly reduces preparation time and could improve the safe use of our product. We're already getting favorable feedback, with numerous people pointing out that this represents a dramatic improvement compared with the vented vial spike used previously. Finally, in early December 2024, the U.S. District Court decided in favor of Heron and our patent lawsuit against Fresenius Kabi, upholding the validity of the CINVANTI patents, which are scheduled to expire in 2035. In spite of all the transformations and achievements across the past 18 months, we managed to reach profitability not just for the fourth quarter of 2024, but for the entire year as well. We closed out the quarter with net income of $3.6 million. For the full year 2024, net revenues hit $144.2 million, which represents a 14% increase year-over-year, and we produced an adjusted EBITDA of $8.6 million. CINVANTI net revenues recovered from a modest decline in Q3, ending the fourth quarter at $26.9 million versus $22.7 million in Q3. Across the full year 2024, CINVANTI brought in just over $100 million in net revenues, rising from $94.8 million in 2023. ZYNRELEF hit record net revenues of $8.5 million in Q4 of 2024, a 33% rise from $6.3 million in Q3. This expansion came about with minimal effect from the VAN launch, since it was rolled out in mid-December. To underscore the advancement since we came to Heron in April of 2023, it's useful to look back at the financials spanning 2022 through 2024. Net revenues climbed 14% from '23 to '24, while gross margin got better by 24%, going from 49% to roughly 73%. Operating expenses have come down by more than $80 million since 2022; we closed 2024 with a cash balance of just over $59 million. This has been a lengthy journey, but I'm extraordinarily proud of every Heron team member for their sacrifices in turning this business around and reaching profitability in 2024. Now moving on to product performance. Our oncology franchise, which encompasses both CINVANTI and SUSTOL, keeps showing growth even in a highly competitive environment. During our previous quarterly earnings call, we noted that these products may see quarter-to-quarter variability, yet they have historically delivered annual growth. For 2025, we've adopted a more cautious stance regarding our CINVANTI outlook, because of heightened competition coming into the market along with possible pressure on our average selling price. Although we continue to expect unit sales growth in 2025, that growth could occur at a reduced price point, which might affect net revenues for the oncology franchise. Turning to the acute hospital portion of our business. APONVIE and ZYNRELEF both posted substantial growth, rising more than 310% and 48%, respectively, in Q4 of 2024 versus the same period a year earlier. With APONVIE, we're starting to observe a dramatic change in trends, especially in average daily units and the count of ordering accounts. We think this growth will persist in 2025 and beyond as our pull-through efforts broaden product usage among hospital institutions. In addition, we expect additional growth as we keep adding new accounts via P&T wins and system-wide conversions. A comparable pattern is taking shape with ZYNRELEF. Our daily unit sales continue to climb steadily, and we're bringing on new accounts far more quickly than before. We reached record net revenues this quarter even though the VAN did not officially launch until mid-December and our team was still completing training for some of our CrossLink partners. We're thrilled about the robust momentum behind ZYNRELEF as we move into 2025. The work and achievements of the past 18 months are already producing results, and we believe that as the year goes on, ZYNRELEF will see a major upward inflection, ultimately surpassing performance expectations. I'll now hand the call to Ira Duarte, our CFO, to discuss our financials and update our financial guidance. Go ahead, Ira.

Ira Duarte

executive
#3

Thanks, Craig. We keep getting better at running the finances efficiently even as revenues rise. Across the last 12 months, a stretch when the company went through change and disruption, our revenue climbed 13.6%, gross margin went from 48.8% up to 73.2%, and gross profit rose by nearly 71%. What matters even more is that we accomplished this while using only about $21 million in cash during 2024. Product gross profit for the 3 months that ended December 31, 2024, came in at $30.6 million, or 74.9%, up from 71.1% in the same period of 2023. The main reason was that this quarter did not include the sizable inventory write-offs that hit us in the comparable quarter of 2023. On a year-to-date basis, product gross profit reached $105.6 million, or 73.2%, versus $43.7 million, or 48.8%, in the same period of 2023. SG&A expenses for the 3 and 12 months ended December 31, 2024, were $23.2 million and $100.5 million, respectively, compared with $26.8 million and $133.4 million, respectively, in the same period of 2023. That decline came mainly from lower personnel and related costs owing to the reductions in force in prior years, along with better cost efficiencies across all departments. These decreases were offset by higher legal expenses tied to the patent litigations. Research and development expenses were $3.2 million and $16.7 million for the 3 and 12 months ended December 31, 2024, compared to $7.8 million and $39.1 million in the comparable periods of 2023. That decrease was primarily tied to lower personnel and related costs from the reductions in force implemented in previous years, as well as a reduction in development activities. We posted net income of $3.7 million for the 3 months ended December 31, 2024, and a net loss of $13.6 million for the year ended December 31, 2024. In the comparable periods of 2023, our net losses were $10.7 million and $110.6 million, respectively. Cash and short-term investments at December 31, 2024, stood at $59.3 million. Year-to-date, we incurred inventory write-offs of $2.5 million. Also, as noted on earlier calls, we recorded asset impairment write-offs of $2.2 million, mainly tied to projects that are no longer part of the company's forward-looking strategy. Had we excluded depreciation, stock-based compensation, inventory write-offs and the asset impairment write-offs, our adjusted EBITDA results would have shown a positive $8.6 million operating income, which marks a substantial turnaround in the financial management of the business. We are providing product revenues net guidance range of $153 million to $163 million and adjusted EBITDA guidance range of $0 million to $8 million; and now we would like to open the call for any questions.

Brandon Folkes

analyst
#4

Nice work on such a solid quarter. First off, perhaps regarding how ZYNRELEF did during this period — was there any inventory build or similar? Or is that roughly the way we ought to view ZYNRELEF moving ahead? Then, still on ZYNRELEF, have any accounts returned — ones that might not have used ZYNRELEF before the VAN launch — and asked questions about the VAN launch? You mentioned bringing on new accounts at quite a robust pace. Looking at 2025 strategically, is the plan to push deeper use among the existing high-user accounts? Or ought we to consider expanding the number of accounts, or both?

Craig Collard

executive
#5

Thank you, Brandon. Sure, let me start by addressing ZYNRELEF's Q4 results. There truly isn't any stocking or anything of that nature within those revenues. In fact, inventory levels have stayed pretty low. We're sitting at roughly a 2-week to 3-week supply. And VAN didn't really roll out completely until around mid-December of '24; thus, I'd say the effect was pretty small. What I can share is that the response to VAN thus far has been outstanding, in terms of it simply being far easier to use and delivering an improved customer experience. But we've — as of now, I believe we've had no fewer than 15 accounts that either we retained or that returned as part of the VAN rollout. And once more, that's more around the January period that we've observed that. So I expect we'll keep seeing quite robust expansion, given the tailwinds behind this product: the NOPAIN Act, the CrossLink partnership genuinely beginning to kick in and gain traction, plus the VAN launch and the expanded label too. So we've been really delighted with how things have gone up to now. We truly see this product taking off as we get further into the year. Another point about VAN: so far we've only rolled out the 400 milligram. We do have kits allowing a switch to the 200-milligram, yet the 200-milligram won't be fully released until roughly the April period, which gives us time to drain the older inventory that existed. So I think as we get toward midyear, you'll genuinely notice a shift, since VAN will be complete, with no more vented valve spike remaining on the market.

Brandon Folkes

analyst
#6

Great. Then perhaps only one more regarding the cash flow adjusted EBITDA, so to speak. Clearly, that was a really strong year in this area. Thank you for the 2025 guidance. In what way should we consider it, say, quarter by quarter? Might there be a certain amount of unevenness, just in the sense of moving back and forth between positive and negative EBITDA or cash flow during the first half, and then, as that VAN increases, we finish the year with steady positive cash flow? Or do you believe we've reached a point where positive cash flow ought to be expected each quarter?

Ira Duarte

executive
#7

Yes, Brandon, thanks for asking. Yes, it's going to be somewhat uneven, mainly due to a portion of the legal spend along with the PFS; that is truly what's having some effect on our quarters. On the whole, the results and the spend won't shift meaningfully versus this year. However, those are the 2 things that might introduce a bit of unevenness early in the year.

Craig Collard

executive
#8

Right, Brandon — one more thing from my side. The area where we've perhaps been somewhat cautious is CINVANTI. Looking at how the product stands at present, our trajectory is quite near where it stood during the same period a year ago. In that category, growth of the market is usually somewhere between 7% and 8%, and our share has stayed at approximately 27%. We had expected rivals to emerge in the later portion of the year, along with a modest decline in ASP. Yet based on where things stand right now, we're running quite near last year's level. That's why we've aimed to stay somewhat conservative in that regard. So that's one more element that might shift somewhat.

Serge Belanger

analyst
#9

I've got a few things to ask about ZYNRELEF. Seems like this product is picking up steam right now. Could you perhaps explain what's behind that acceleration, and also what you're anticipating from NOPAIN when it becomes active for ZYNRELEF, which as I understand it happens in March or April?

Craig Collard

executive
#10

Yeah, you've got that right. Well, honestly, I'd say the traction we've seen has made us quite happy. Again, I brought up those favorable conditions earlier. On the reimbursement side, though, things won't kick in completely until April 1. Still, what I believe matters more is all the buzz surrounding NOPAIN and, in a sense, the encouragement to consider options that aren't opioids. That will benefit us, and truly anyone out there in this space offering such products; so my feeling is it's going to be enormously beneficial for us. Could you remind me how your question ended? My apologies.

Serge Belanger

analyst
#11

Sure. What fueled the momentum during Q4, and would NOPAIN cause that to pick up?

Craig Collard

executive
#12

Yeah. No, no, no — apologies. I meant to address CrossLink. So here's how I see it: the CrossLink partnership is genuinely beginning to deliver. In terms of how we analyze our numbers, whenever there's an overlap with a CrossLink counterpart, we treat that as a CrossLink account rather than one where we're present, so to speak, or a hospital system where we are but CrossLink isn't. What I can share is that those accounts are expanding roughly 30% faster than what you might call our typical stand-alone business. So our expectation is that this simply keeps going. With VAN, and once again, as we sharpen our approach and align more effectively with our CrossLink counterparts, we anticipate some upside as we head toward the 200-milligram launch later this year. And as we get into roughly midyear, in Q3, I believe things will truly begin running far more smoothly. Again, we currently have 800 people in the field who are essentially just now getting going with VAN. The way all of that comes together, I'd say, is shaping up well. Still, the growth we've seen up to this point looks quite different from what we had previously, and my sense is that will keep holding true.

Serge Belanger

analyst
#13

Alright, and looking at 2025 from an OpEx angle, is it fair to think growth will be roughly flat compared with 2024?

Ira Duarte

executive
#14

Correct, though it'll come in somewhat above 2024, purely because of the R&D spending tied to PFS, which wasn't there in 2024, plus certain legal costs as we work to resolve a number of the outstanding cases. So on the whole, the rest of the business stays essentially flat, but those 2 things could push OpEx up a bit in 2025 or 2024.

Carl Byrnes

analyst
#15

Nice work on the progress. You saw a solid lift with ZYNRELEF, hitting $8.5 million. Given how NOPAIN is timed and how the VAN approval is timed, should we expect a comparable lift in the first quarter? And then could you perhaps extend that thinking a bit further — with the count of CrossLink reps who've been trained to market the VAN, how might that drive a potential inflection point in the back half of the year when it comes to meaningfully accelerating ZYNRELEF sales? And the same question applies regarding APONVIE.

Craig Collard

executive
#16

Yes. No, Carl, like we've mentioned, I believe right now we're sitting at roughly 800 — or about 800 CrossLink reps. And those final 100 or so were kind of being brought together during Q4. So once more, as we exit — as we enter '25, that's the point where this starts to — in our view it begins to fire on all cylinders as we progress through the year; so that's roughly where things stand at present. Again, with CrossLink joining and as we examine the shift from Q4 into Q1, you know, there's usually some seasonality around co-pay resets and similar factors that in the past have softened the market. What I can share is that we are — right now, when I look at something like daily average sales, we're in fact running higher so far in Q1 than we did in Q4. So once more, we're hoping that keeps up. Naturally, the market has somewhat fewer surgeries overall in Q1. But still, we're expecting to keep growing. And so as we look ahead more toward midyear, once more, I believe as we roll out the 200-milligram VAN, with NOPAIN truly gaining traction, I think generating more buzz, that's genuinely where we see the inflection taking shape. And the other benefit CrossLink brings us is that as more of them join and can step into our spots during surgeries and feel more at ease with the product, it frees our reps to get away from those surgeries day to day, and CrossLink turns into our eyes and ears; and because of that, it truly lets our reps get out and not just locate additional surgeons and other people in the hospital, reaching further and broader, so to speak, inside an institution, but it also gives us more time to devote to APONVIE. And once again, we're quite confident we'll keep growing APONVIE at a very different rate — and if you consider what APONVIE can do in terms of really achieving systematic wins, our challenge up to now has really been getting our representatives out of the OR and enabling them to drive more pull-through with the product. And once more, we believe CrossLink will help enormously with that.

Carl Byrnes

analyst
#17

Great. Great. So I mean, it's pretty obvious that a shift is happening—growth is clearly coming from the acute care products, while the CINV products are really acting as kind of a cash cow that props up cash flow. And just one more follow-up question. Do you have any thoughts regarding the Baker Brothers debt?

Craig Collard

executive
#18

Yes. No, we've—I mean, when it comes to the Baker Brothers, obviously, they hold a large debt position for us and have been a wonderful partner. We've kept meeting with them every quarter. I think now that we're getting close to sort of the May '26 timeframe, we plan to meet with them once more. Again, we wanted to get our quarter announced and so forth, and really feel that given where the business is heading, we're hoping all of our investors would be excited; but we should be sitting down with them very soon and to discuss options with the convert and sort of where we can go from there.

Carl Byrnes

analyst
#19

Yes, and my guess is that since the CINVANTI litigation is mostly behind us, that sort of paves the way for those talks.

Craig Collard

executive
#20

Yeah. No, that had been — clearly, it was something unknown. But I believe at this point we've got clarity on it. And once more, even the Mylan matter closely resembles what we dealt with in the Fresenius situation. So our confidence on that is quite high. But yeah, it will definitely be beneficial for those conversations.

Clara Dong

analyst
#21

Congratulations on what was achieved during the quarter. I was just curious — after ZYNRELEF became available back in mid-December, it appears the ramp-up has been going quite well. So I wanted to ask, might you provide an update regarding the prefilled syringe for ZYNRELEF and where things currently stand?

Craig Collard

executive
#22

Sure. Thank you, Claire. Bill Forbes has joined this call. When it comes to that development path and its current status, I'll have Bill respond.

Bill Forbes

executive
#23

Thanks for asking that. So, to give everyone a bit of an update, we couldn't be happier with how the VAN launch has gone. The folks working on device development that we have on staff have been monitoring it very closely while our commercial partners have been pushing it forward. Now, shifting over to the prefilled syringe, I'd like to briefly go back over some of what I discussed at last year's Investor Day meeting. One issue we have to keep an eye on when it comes to ZYNRELEF is moisture content. Roughly 12 months ago, we set up what you could call a demonstration batch for stability testing; we've now gotten to the 9-month mark on that, and the way both the stability and that demo batch have performed has made us very happy; because of that, our confidence in this program has gone up considerably. That said, we're aiming to bring it to market at some point close to the end of 2026 or during the first half of 2027; work on it keeps moving ahead. If anything else comes to mind, I'm glad to take those questions.

Craig Collard

executive
#24

Thanks, operator. So, we’re grateful to have all of you with us on today’s call; clearly, we’re quite enthusiastic about the position we’re in as a business, the base we’ve established at this point, and the way we’re heading into '25; so we’re eager to speak with all of you again in the next quarter. Thank you.

Operator

operator
#25

We appreciate all of our speakers; that brings an end to the conference call for today. Thanks for joining us. You're welcome to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Heron Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to Heron Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Heron Therapeutics, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.